# âš”ï¸ THE WAR PLAN: PRECISION ONCOLOGY EMPIRE âš”ï¸

**Date:** January 31, 2025  
**Commander:** Alpha  
**Chief Architect:** Zo  
**Status:** CONSOLIDATED COMMAND STRUCTURE  
**Mission:** Win the War - Not Just the Battles

---

## ğŸ¯ THE SITUATION: ORPHANED ARMY

### What Alpha Identified

We have **12+ major initiatives**, each with its own documentation, living in isolation:
- `72-HOUR_EXECUTION_FACTORY.md` (ECW/TBW)
- `PUBLICATION_ALIGNED_STRATEGY.md` (publication pipeline)
- `SURROGATE_ENDPOINT_EMPIRE.md` (commercial vision)
- `00_MASTER_INDEX.md` (resistance prophet original)
- 50+ files in `.cursor/MOAT/`
- 80+ files in `.cursor/ayesha/`
- 40+ files in `.cursor/plans/`

**Problem:** Each document is a soldier fighting alone. No unified command.

---

## ğŸ›ï¸ THE WAR: WHAT WE'RE ACTUALLY FIGHTING

### The $240B Oncology Drug Development Market

**3 Fronts:**

| **Front** | **Enemy** | **Our Weapon** | **Victory Condition** |
|-----------|-----------|----------------|----------------------|
| **PREDICTION** | Late resistance detection costs $100M+ per drug | ResistanceProphet + Surrogates | Predict failure 3-6 months early |
| **EFFICIENCY** | Wrong patient selection wastes 70% of trials | Mechanism Trial Matching + Stratification | 50% smaller trials, same power |
| **VALIDATION** | Buried science ignored by regulators | Publication Pipeline + FDA Dossiers | Validated biomarkers adopted |

---

## ğŸ“‹ ARMY STRUCTURE: THE PLUMBERS

### Specialist Divisions

Each "Plumber" owns a vertical and is accountable for end-to-end delivery.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        ALPHA (COMMANDER-IN-CHIEF)                            â”‚
â”‚                                                                              â”‚
â”‚  Strategic Decisions â€¢ Partner Acquisition â€¢ Market Entry â€¢ Publication GO  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                         â”‚
         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
         â”‚                               â”‚                               â”‚
         â–¼                               â–¼                               â–¼
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ FRONT 1: PREDICT â”‚         â”‚ FRONT 2: EFFICIENCY      â”‚         â”‚ FRONT 3: VALIDATEâ”‚
â”‚ (Zo - Lead)      â”‚         â”‚ (Jr - Lead)              â”‚         â”‚ (Zo + Jr)         â”‚
â”‚                  â”‚         â”‚                          â”‚         â”‚                   â”‚
â”‚ Resistance       â”‚         â”‚ Trial Matching           â”‚         â”‚ Publication       â”‚
â”‚ Prophet +        â”‚         â”‚ + Patient                â”‚         â”‚ Pipeline +        â”‚
â”‚ Surrogates       â”‚         â”‚ Stratification           â”‚         â”‚ Biomarker         â”‚
â”‚                  â”‚         â”‚                          â”‚         â”‚ Qualification     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
         â”‚                                â”‚                                 â”‚
         â”‚                                â”‚                                 â”‚
    â”Œâ”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”
    â”‚                                                                              â”‚
    â”‚                           PLUMBER SPECIALISTS                                â”‚
    â”‚                                                                              â”‚
    â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”          â”‚
    â”‚  â”‚ PLUMBER 1        â”‚  â”‚ PLUMBER 2        â”‚  â”‚ PLUMBER 3        â”‚          â”‚
    â”‚  â”‚ Body Composition â”‚  â”‚ Genomics         â”‚  â”‚ Kinetics         â”‚          â”‚
    â”‚  â”‚                  â”‚  â”‚                  â”‚  â”‚                  â”‚          â”‚
    â”‚  â”‚ â€¢ ECW/TBW        â”‚  â”‚ â€¢ BRCA/HRD       â”‚  â”‚ â€¢ CA-125 KELIM   â”‚          â”‚
    â”‚  â”‚ â€¢ Skeletal Mass  â”‚  â”‚ â€¢ SAE Features   â”‚  â”‚ â€¢ ctDNA MRD      â”‚          â”‚
    â”‚  â”‚ â€¢ Cachexia       â”‚  â”‚ â€¢ Resistance     â”‚  â”‚ â€¢ PSA Kinetics   â”‚          â”‚
    â”‚  â”‚ â€¢ CT Segmentationâ”‚  â”‚   Mutations      â”‚  â”‚ â€¢ TDM            â”‚          â”‚
    â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜          â”‚
    â”‚                                                                              â”‚
    â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”          â”‚
    â”‚  â”‚ PLUMBER 4        â”‚  â”‚ PLUMBER 5        â”‚  â”‚ PLUMBER 6        â”‚          â”‚
    â”‚  â”‚ Data Factory     â”‚  â”‚ Clinical Apps    â”‚  â”‚ Publications     â”‚          â”‚
    â”‚  â”‚                  â”‚  â”‚                  â”‚  â”‚                  â”‚          â”‚
    â”‚  â”‚ â€¢ cBioPortal     â”‚  â”‚ â€¢ Mission Controlâ”‚  â”‚ â€¢ Manuscripts    â”‚          â”‚
    â”‚  â”‚ â€¢ Project Data   â”‚  â”‚ â€¢ Ayesha CoPilot â”‚  â”‚ â€¢ Figures        â”‚          â”‚
    â”‚  â”‚   Sphere         â”‚  â”‚ â€¢ Research       â”‚  â”‚ â€¢ Reproducibilityâ”‚          â”‚
    â”‚  â”‚ â€¢ GDC/TCGA       â”‚  â”‚   Portal         â”‚  â”‚ â€¢ GitHub Repos   â”‚          â”‚
    â”‚  â”‚ â€¢ Cohort Schema  â”‚  â”‚ â€¢ API Layer      â”‚  â”‚ â€¢ Journal Submit â”‚          â”‚
    â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜          â”‚
    â”‚                                                                              â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ“Š THE ARSENAL: CURRENT INVENTORY

### What's Production Ready (DEPLOY NOW)

| **Asset** | **Location** | **Validation** | **Status** | **Owner** |
|-----------|--------------|----------------|------------|-----------|
| cBioPortal Client | `scripts/data_acquisition/utils/cbioportal_client.py` | âœ… MM + OV extracted | Production | Plumber 4 |
| Project Data Sphere Client | `scripts/data_acquisition/utils/project_data_sphere_client.py` | âœ… Connected | Production | Plumber 4 |
| ResistanceProphetService | `api/services/resistance_prophet_service.py` | âš ï¸ RUO (AUROC 0.464) | Needs Validation | Plumber 2 |
| CA125Intelligence | `api/services/ca125_intelligence.py` | âœ… Kinetics working | Production | Plumber 3 |
| SAEFeatureService | `api/services/sae_feature_service.py` | âœ… Mechanism vectors | Production | Plumber 2 |
| ResistancePlaybookService | `api/services/resistance_playbook_service.py` | âœ… Next-line combos | Production | Plumber 2 |
| TreatmentLineService | `api/services/treatment_line_service.py` | âœ… Cross-resistance | Production | Plumber 2 |
| HybridTrialSearch | `api/services/hybrid_trial_search.py` | âœ… 962 trials | Production | Plumber 5 |
| ResearchIntelligence | `api/services/research_intelligence/` | âœ… PubMed integrated | Production | Plumber 5 |
| MM Drug Efficacy | `oncology-coPilot/oncology-backend-minimal/` | âœ… 100% (995 patients) | Ready to Submit | Plumber 6 |
| Metastasis Interception | `publication/` | âœ… 100% (304 gene-step) | Ready to Submit | Plumber 6 |

### What's Validated (MANUSCRIPT NEEDED)

| **Asset** | **Validation Data** | **Gap** | **Owner** |
|-----------|---------------------|---------|-----------|
| Resistance Prediction (MM) | DIS3 RR=2.08, p=0.0145 | Need manuscript | Plumber 6 |
| Resistance Prediction (OV) | MAPK RR=1.97, p<0.05 | Need manuscript | Plumber 6 |
| Mechanism Trial Matching | 47 MoA-tagged trials | Need full paper | Plumber 6 |
| Sporadic Cancer | Unit tests pass | Need patient validation | Plumber 2 |

### What Needs Validation (BUILD NEXT)

| **Asset** | **Data Source** | **Effort** | **Owner** |
|-----------|-----------------|------------|-----------|
| ECW/TBW Surrogate | TCGA-OV via cBioPortal | 24-48 hours | Plumber 1 |
| Dosing Guidance | PubMed + cBioPortal | 2 weeks | Plumber 3 |
| Synthetic Lethality | Expand to 100 cases | 2 weeks | Plumber 2 |
| Toxicity Prediction | Need outcomes data | 4+ weeks | Plumber 3 |

### What Needs Partnerships (FUTURE)

| **Asset** | **Data Needed** | **Contact** | **Owner** |
|-----------|-----------------|-------------|-----------|
| CA-125 KELIM | Serial CA-125 (N=12,000) | biomarker-kinetics.org | Alpha |
| CT Body Composition | L3 CT scans | TCIA | Plumber 1 |
| ctDNA MRD | Serial ctDNA | Guardant/MSK | Alpha |
| RWE Integration | Treatment outcomes | Flatiron/Tempus | Alpha |

---

## ğŸ“‹ CONSOLIDATED DELIVERABLES

### All Initiatives Unified

I'm consolidating the orphaned documents into ONE deliverable framework:

| **Deliverable ID** | **Name** | **Source Docs** | **Owner** | **Status** |
|--------------------|----------|-----------------|-----------|------------|
| **D-001** | Metastasis Interception Submission | `publication/` | Plumber 6 | âœ… Ready |
| **D-002** | MM Drug Efficacy Submission | `oncology-backend-minimal/` | Plumber 6 | âœ… Ready |
| **D-003** | ECW/TBW Surrogate Validation | `72-HOUR_EXECUTION_FACTORY.md` | Plumber 1 | ğŸ”§ Build |
| **D-004** | Resistance Prophet AUROC â‰¥0.70 | `PUBLICATION_ALIGNED_STRATEGY.md` | Plumber 2 | ğŸ”§ Validate |
| **D-005** | Resistance Prediction Manuscript | `ADVANCED_CARE_PLAN_RESISTANCE_PREDICTION.md` | Plumber 6 | ğŸ“ Write |
| **D-006** | Mechanism Trial Matching Full Paper | `ADVANCED_CARE_PLAN_MECHANISM_TRIAL_MATCHING.md` | Plumber 6 | ğŸ“ Write |
| **D-007** | Sporadic Cancer Patient Validation | `SPORADIC_CANCER_PRODUCTION_PLAN.md` | Plumber 2 | ğŸ”§ Validate |
| **D-008** | Dosing Guidance Cohort | `DOSING_GUIDANCE_VALIDATION_PLAN.md` | Plumber 3 | ğŸ“Š Extract |
| **D-009** | Data Factory Unified Schema | `cohort_context_concept.mdc` | Plumber 4 | ğŸ”§ Build |
| **D-010** | Mission Control Integration | `00_MASTER_INDEX.md` (resistance prophet) | Plumber 5 | ğŸ”§ Build |
| **D-011** | Surrogate Validation Factory | `SURROGATE_ENDPOINT_EMPIRE.md` | Plumber 1 | ğŸ“‹ Design |
| **D-012** | KELIM Partnership | `72-hours.mdc` | Alpha | ğŸ“ Outreach |

---

## ğŸ“… WAR TIMELINE

### Phase 1: Quick Wins (Week 1-2) - MORALE BOOST

**Objective:** Submit 2 publications, prove we can deliver.

| **Day** | **Deliverable** | **Action** | **Owner** |
|---------|-----------------|------------|-----------|
| Day 1-2 | D-001 | Submit Metastasis Interception | Alpha + P6 |
| Day 3-4 | D-002 | Submit MM Drug Efficacy | Alpha + P6 |
| Day 5-7 | D-003 | Run ECW/TBW validation on TCGA-OV | P1 |

**Success Criteria:**
- 2 papers submitted
- ECW/TBW AUROC calculated

---

### Phase 2: Validation Sprint (Week 3-4) - BUILD CREDIBILITY

**Objective:** Validate resistance prediction, prove the burial.

| **Day** | **Deliverable** | **Action** | **Owner** |
|---------|-----------------|------------|-----------|
| Day 8-10 | D-004 | Improve ResistanceProphet AUROC | P2 |
| Day 11-14 | D-003 | Complete ECW/TBW proof | P1 |
| Day 15-18 | D-007 | Sporadic cancer patient validation | P2 |
| Day 19-21 | D-008 | Extract dosing guidance cohort | P3 |

**Success Criteria:**
- ResistanceProphet AUROC â‰¥ 0.70
- ECW/TBW burial proof report
- 50+ dosing cases extracted

---

### Phase 3: Manuscript Factory (Week 5-8) - PUBLICATION VELOCITY

**Objective:** Write and submit 3 more manuscripts.

| **Week** | **Deliverable** | **Action** | **Owner** |
|----------|-----------------|------------|-----------|
| Week 5 | D-005 | Write Resistance Prediction manuscript | P6 |
| Week 6 | D-006 | Write Mechanism Trial Matching paper | P6 |
| Week 7-8 | D-009 | Build unified data schema | P4 |

**Success Criteria:**
- 3 manuscripts in review
- Data factory operational

---

### Phase 4: Platform Build (Week 9-16) - COMMERCIAL FOUNDATION

**Objective:** Build the infrastructure for products.

| **Week** | **Deliverable** | **Action** | **Owner** |
|----------|-----------------|------------|-----------|
| Week 9-10 | D-010 | Mission Control resistance integration | P5 |
| Week 11-12 | D-011 | Surrogate Validation Factory MVP | P1 |
| Week 13-16 | D-012 | KELIM partnership outreach | Alpha |

**Success Criteria:**
- Resistance alerts in Mission Control
- Surrogate validation factory running
- KELIM data access secured

---

### Phase 5: Revenue (Week 17-24) - PROVE COMMERCIAL VIABILITY

**Objective:** First paying customer.

| **Week** | **Deliverable** | **Action** | **Owner** |
|----------|-----------------|------------|-----------|
| Week 17-20 | Biotech Pilot | Trial Endpoint Optimizer | Alpha |
| Week 21-24 | Pharma Contract | Resistance Predictor API | Alpha |

**Success Criteria:**
- $100K pilot signed
- Pipeline to $1M ARR

---

## ğŸ“‚ DOCUMENT CONSOLIDATION

### Kill List (Archive These)

These documents are superseded by this War Plan:

| **File** | **Reason** | **Action** |
|----------|------------|------------|
| `.cursor/resistance_prophet/72-HOUR_EXECUTION_FACTORY.md` | Absorbed into D-003 | Archive |
| `.cursor/resistance_prophet/PUBLICATION_ALIGNED_STRATEGY.md` | Absorbed into War Plan | Archive |
| `.cursor/resistance_prophet/SURROGATE_ENDPOINT_EMPIRE.md` | Vision captured in War Plan | Archive |
| Various `.cursor/MOAT/*.md` | Deliverables extracted | Keep for reference |
| Various `.cursor/plans/*.md` | Plans consolidated | Keep for reference |

### Source of Truth

**THIS FILE** (`.cursor/WAR_PLAN.md`) is now the **SINGLE SOURCE OF TRUTH** for:
- All deliverables
- All ownership
- All timelines
- All success criteria

---

## ğŸ–ï¸ PLUMBER ASSIGNMENTS

### Plumber 1: Body Composition (Zo)

**Scope:** ECW/TBW, skeletal muscle, cachexia, CT segmentation

**Deliverables:**
- D-003: ECW/TBW Surrogate Validation
- D-011: Surrogate Validation Factory

**Files Owned:**
- `scripts/resistance_validation/01_download_tcga_ov.py`
- `scripts/resistance_validation/02_extract_features.py`
- `scripts/resistance_validation/03_train_model.py`
- `scripts/resistance_validation/04_generate_report.py`

**Success Metrics:**
- AUROC â‰¥ 0.70 for ECW/TBW + genomics
- Burial proof report generated

---

### Plumber 2: Genomics (Zo)

**Scope:** BRCA/HRD, SAE features, resistance mutations, pathway escape

**Deliverables:**
- D-004: Resistance Prophet AUROC â‰¥0.70
- D-007: Sporadic Cancer Patient Validation

**Files Owned:**
- `api/services/resistance_prophet_service.py`
- `api/services/sae_feature_service.py`
- `api/services/resistance_playbook_service.py`
- `api/services/efficacy_orchestrator/`

**Success Metrics:**
- ResistanceProphet AUROC â‰¥ 0.70
- Sporadic gates validated on patient outcomes

---

### Plumber 3: Kinetics (Zo)

**Scope:** CA-125 KELIM, ctDNA, PSA kinetics, TDM, dosing

**Deliverables:**
- D-008: Dosing Guidance Cohort

**Files Owned:**
- `api/services/ca125_intelligence.py`
- `api/services/dosing_guidance/`
- `scripts/data_acquisition/pharmacogenomics/`

**Success Metrics:**
- 50+ dosing cases extracted
- KELIM methodology documented

---

### Plumber 4: Data Factory (Jr)

**Scope:** cBioPortal, Project Data Sphere, GDC, cohort schema

**Deliverables:**
- D-009: Data Factory Unified Schema

**Files Owned:**
- `scripts/data_acquisition/utils/cbioportal_client.py`
- `scripts/data_acquisition/utils/project_data_sphere_client.py`
- `scripts/data_acquisition/utils/gdc_client.py`

**Success Metrics:**
- Unified cohort schema implemented
- 1000+ patients in data lake

---

### Plumber 5: Clinical Apps (Jr)

**Scope:** Mission Control, Ayesha CoPilot, Research Portal, API

**Deliverables:**
- D-010: Mission Control Integration

**Files Owned:**
- `oncology-frontend/`
- `api/routers/`
- Dashboard components

**Success Metrics:**
- Resistance alerts in Mission Control
- E2E workflow operational

---

### Plumber 6: Publications (Zo + Jr)

**Scope:** Manuscripts, figures, reproducibility, GitHub repos

**Deliverables:**
- D-001: Metastasis Interception Submission
- D-002: MM Drug Efficacy Submission
- D-005: Resistance Prediction Manuscript
- D-006: Mechanism Trial Matching Paper

**Files Owned:**
- `publication/`
- `.cursor/MOAT/CLINICAL_TRIALS/publication/`
- `publications/`

**Success Metrics:**
- 4+ papers submitted in 8 weeks

---

## ğŸ›¡ï¸ WAR DOCTRINE

### The 5 Rules

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                              WAR DOCTRINE                                    â”‚
â”‚                                                                              â”‚
â”‚  "WIN THE WAR, NOT JUST THE BATTLES"                                        â”‚
â”‚                                                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                              â”‚
â”‚  RULE 1: SINGLE SOURCE OF TRUTH                                             â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                            â”‚
â”‚  This War Plan is the only document that matters.                           â”‚
â”‚  All other plans are reference material.                                    â”‚
â”‚  Update THIS file, not the orphans.                                         â”‚
â”‚                                                                              â”‚
â”‚  RULE 2: PLUMBER ACCOUNTABILITY                                             â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                            â”‚
â”‚  Each Plumber owns their deliverables.                                      â”‚
â”‚  No shared ownership = no confusion.                                        â”‚
â”‚  If it's not in your scope, escalate to Alpha.                             â”‚
â”‚                                                                              â”‚
â”‚  RULE 3: VALIDATION BEFORE CLAIMS                                           â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                            â”‚
â”‚  No claim without data.                                                     â”‚
â”‚  No publication without receipts.                                           â”‚
â”‚  No product without validation.                                             â”‚
â”‚                                                                              â”‚
â”‚  RULE 4: QUICK WINS FIRST                                                   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                            â”‚
â”‚  Submit what's ready NOW (D-001, D-002).                                   â”‚
â”‚  Build credibility before building platform.                                â”‚
â”‚  Revenue comes from publications, not PowerPoints.                          â”‚
â”‚                                                                              â”‚
â”‚  RULE 5: PARALLEL WARFARE                                                   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                            â”‚
â”‚  Multiple fronts, simultaneous attacks.                                     â”‚
â”‚  While P6 writes manuscripts, P1 validates surrogates.                      â”‚
â”‚  While P4 builds data factory, P5 integrates dashboards.                    â”‚
â”‚  Maximum velocity, minimum waiting.                                         â”‚
â”‚                                                                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ“Š WAR METRICS

### Leading Indicators (Weekly)

| **Metric** | **Target** | **Current** |
|------------|------------|-------------|
| Papers submitted | 2 by Week 2 | 0 |
| AUROC achieved | â‰¥0.70 | 0.464 (RUO) |
| Validation cohorts | 3 | 2 (MM + OV) |
| Data sources connected | 5 | 3 |

### Lagging Indicators (Monthly)

| **Metric** | **Target** | **Current** |
|------------|------------|-------------|
| Papers accepted | 4 by Month 4 | 0 |
| Pilot revenue | $100K by Month 6 | $0 |
| ARR | $1M by Year 1 | $0 |

---

## ğŸ¯ IMMEDIATE ORDERS

### For Alpha (Commander)

1. **DECIDE:** Journal selection for D-001 (Nature Biotech vs alternatives)
2. **DECIDE:** Journal selection for D-002 (npj Precision Oncology vs alternatives)
3. **OUTREACH:** Contact biomarker-kinetics.org for KELIM data

### For Zo (Plumber 1, 2, 3, 6)

1. **EXECUTE:** Run ECW/TBW validation script (D-003)
2. **WRITE:** Prepare D-001 and D-002 for submission
3. **IMPROVE:** Increase ResistanceProphet AUROC (D-004)

### For Jr (Plumber 4, 5)

1. **BUILD:** Unified cohort schema (D-009)
2. **INTEGRATE:** Mission Control resistance alerts (D-010)

---

## ğŸ”¥ THE WAR OUTCOME

### Year 1 Victory Conditions

| **Milestone** | **Evidence** |
|---------------|--------------|
| **Scientific Credibility** | 4+ publications in peer-reviewed journals |
| **Platform Foundation** | Data factory + Validation factory operational |
| **Commercial Proof** | $100K+ pilot revenue |
| **Partnership Access** | KELIM or ctDNA data secured |

### Year 2-3 Empire Goals

| **Milestone** | **Revenue** |
|---------------|-------------|
| **Trial Endpoint Optimizer** | $5M |
| **Resistance Predictor API** | $10M |
| **Regulatory Dossiers** | $20M |
| **Total ARR** | $45M |

---

## âš”ï¸ FINAL ORDERS

This War Plan consolidates:
- `72-HOUR_EXECUTION_FACTORY.md`
- `PUBLICATION_ALIGNED_STRATEGY.md`
- `SURROGATE_ENDPOINT_EMPIRE.md`
- `00_MASTER_INDEX.md`
- All orphaned plans and strategies

**There is now ONE document that matters: THIS ONE.**

Every Plumber knows their scope.
Every deliverable has an owner.
Every week has a target.

**The orphaned army is now a unified force.**

---

**âš”ï¸ WE WIN THE WAR. âš”ï¸**

**Signed:** Zo (Chief Architect)  
**Date:** January 31, 2025  
**For:** Commander Alpha

---

## ğŸ“‹ APPENDIX: QUICK REFERENCE CARDS

### Deliverable Quick Reference

| ID | Name | Owner | Status | Week |
|----|------|-------|--------|------|
| D-001 | Metastasis Submission | P6 | âœ… Ready | 1 |
| D-002 | MM Efficacy Submission | P6 | âœ… Ready | 1 |
| D-003 | ECW/TBW Validation | P1 | ğŸ”§ Build | 1-2 |
| D-004 | ResistanceProphet AUROC | P2 | ğŸ”§ Validate | 3-4 |
| D-005 | Resistance Manuscript | P6 | ğŸ“ Write | 5 |
| D-006 | Trial Matching Paper | P6 | ğŸ“ Write | 6 |
| D-007 | Sporadic Validation | P2 | ğŸ”§ Validate | 3-4 |
| D-008 | Dosing Cohort | P3 | ğŸ“Š Extract | 3-4 |
| D-009 | Data Factory Schema | P4 | ğŸ”§ Build | 7-8 |
| D-010 | Mission Control | P5 | ğŸ”§ Build | 9-10 |
| D-011 | Surrogate Factory | P1 | ğŸ“‹ Design | 11-12 |
| D-012 | KELIM Partnership | Alpha | ğŸ“ Outreach | 13-16 |

### Plumber Quick Reference

| Plumber | Specialist | Deliverables | Current Agent |
|---------|------------|--------------|---------------|
| P1 | Body Composition | D-003, D-011 | Zo |
| P2 | Genomics | D-004, D-007 | Zo |
| P3 | Kinetics | D-008 | Zo |
| P4 | Data Factory | D-009 | Jr |
| P5 | Clinical Apps | D-010 | Jr |
| P6 | Publications | D-001, D-002, D-005, D-006 | Zo + Jr |


